Data for investigational CD20xCD3 bispecific antibodies and new combination regimens with Polivy showed enhanced clinical benefits for people with non-Hodgkin lymphoma in early studies Basel, 4 June 2021 ‒ Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data on its investigational CD20xCD3 T-cell engaging bispecific antibodies, mosunetuzumab and glofitamab, and its first-in-class anti-CD79b... Read more
With hypomethylating agents significantly improved complete response rates in certain adults with newly diagnosed acute myeloid leukaemia In the VIALE-A study, Venclyxto plus azacitidine significantly improved overall survival in patients ineligible for intensive chemotherapy, a patient population who typically have a five-year overall survival rate of less than 10%1 Study data reinforces the potential of... Read more
Tecentriq improved disease-free survival by more than one-third in people with PD-L1-positive resectable early-stage lung cancer, compared with best supportive care First and only cancer immunotherapy to show positive Phase III results in the adjuvant lung cancer setting New adjuvant treatment options are urgently needed in early lung cancer to help the approximately 50% of... Read more
Data from the first positive phase III study of a cancer immunotherapy in early, resected lung cancer Studies in personalised healthcare exploring tumour agnostic treatments that demonstrate the impact of coupling biomarker testing with targeted therapies to develop individualised treatment plans New data, and drug combination strategies for the treatment of lymphoma from the largest... Read more
Tecentriq significantly improved overall survival in people with high PD-L1 expression, compared with chemotherapy in a Phase III study Tecentriq approval offers an alternative to chemotherapy for all eligible patients This approval marks Tecentriq’s fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall in the EU Basel, 5 May... Read more
Basel, 28 April 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 1 in favour of maintaining accelerated approval of Tecentriq® (atezolizumab) for the treatment of adults with locally advanced or metastatic urothelial carcinoma (mUC, bladder cancer) who are... Read more
Cardiovascular diseases are responsible for 17.9 million deaths every year¹, a third of all deaths globally² Roche announces five new intended uses for key cardiac biomarkers to help identify cardiovascular risk, better diagnose patients and support early treatment Early diagnosis and treatment can contribute to saving or improving people’s lives and could help healthcare systems... Read more
Basel, 28 April 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 7 to 2 in favour of maintaining accelerated approval of Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel) for the treatment of adults with unresectable locally... Read more
If approved, ENSPRYNG will be the first and only treatment available to both adults and adolescents from 12 years of age with anti-aquaporin-4 antibody (AQP4-IgG) seropositive NMOSD in the EU ENSPRYNG is the only subcutaneous treatment option for NMOSD that can be administered at home every four weeks Recommendation is based on results from the... Read more
About 90,000 women globally die from endometrial cancer each year1 VENTANA MMR RxDx Panel is the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1 immunotherapy JEMPERLI (dostarlimab-gxly) Roche/GSK collaboration represents an important step towards a personalised healthcare strategy that can help identify patients who are most likely to benefit from a... Read more